News & Updates

In cancer patients with isolated distal deep vein thrombosis (IDDVT), a 12-month anticoagulation regimen with the oral factor Xa inhibitor edoxaban fared better than a 3-month regimen, findings from the ONCO DVT study have shown.

Colorectal cancer screening should wait until age 50 for average-risk, asymptomatic adults, says the American College of Physicians (ACP) in its updated guidance. However, this stands in contrast to screening recommendations by the American Cancer Society (ACS) and the US Preventive Services Task Force (USPSTF) to start at age 45.

In the treatment of patients with nonresectable colorectal cancer (CRC) with liver metastases, liver transplantation may improve long-term survival outcomes especially when performed for those with favourable prognostic scoring, according to a study.

Patients with chronic myeloid leukaemia (CML) appear to be unaware or have low acceptance of a healthcare app specifically develop to manage their disease, reports a study.

Ultraviolet (UV)-B phototherapy does not appear to increase the risk of skin cancer in patients with atopic dermatitis (AD), reveals a study.

In the treatment of patients with programmed cell death ligand 1 (PD-L1)-positive, unresectable, and locally advanced nonsmall cell lung cancer (NSCLC), the use of durvalumab immunotherapy in combination with curative radiotherapy yields survival gains with tolerable adverse events (AEs), as shown in the results of the phase II DOLPHIN trial.

Exposure to high levels of fine particulate matter (PM2.5) appears to contribute to an increased risk of oestrogen receptor (ER)-positive breast cancer, as shown in a study.

In the COSMIC-313 trial, the addition of the tyrosine kinase inhibitor (TKI) cabozantinib to the immune checkpoint inhibitor (ICI)-doublet regimen comprising nivolumab and ipilimumab (NIVO/IPI) improved progression-free survival (PFS) in patients with previously untreated, advanced renal-cell carcinoma (RCC) who had intermediate or poor prognostic risk according to the IMDC* category.

Perioperative nivolumab plus platinum-based chemotherapy improves pathological complete response (pCR) rate and survival outcomes vs neoadjuvant platinum-based chemotherapy alone in patients with resectable stage IIIA/B non-small-cell lung cancer (NSCLC), results of the NADIM II trial have shown.